CG Oncology reported that PIVOT-006 met its primary endpoint, with cretostimogene reducing recurrence risk by 68% (hazard ratio 0.32; 95% CI: 0.23, 0.45; p<0.0001). BLAs are planned for March 2027 and the second quarter of 2027.
CGON · CG Oncology, Inc.
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Key stats
- Short volume, last session
- 51%
- Latest filing
- 10-Q · Nov 6
- Price history
- Jan 2024 to Nov 2026
Latest documents
CG Oncology reported a $196.1 million net loss for the nine months ended September 30, 2026, up from $119.7 million, as R&D expenses increased to $137.6 million. Cash, cash equivalents and marketable securities totaled $984.5 million.
CG Oncology reported a $56.9 million third-quarter net loss and expects PIVOT-006 Phase 3 topline data in November 2026, with $984.5 million in cash funding operations through 2029.
Metrics snapshot
Useful current figures from the complete screener profile.
Quarterly results
* Q4 derived as the full year minus Q1 to Q3.
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Strong BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
Earlier KPI extraction records exist, but do not meet the current evidence-completeness requirements. No current verified series is available. Earlier figures remain withheld until revalidated; this is not evidence that the company reports no KPIs.
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CGON
this stock
CG Oncology, Inc.
|
$7.32B | +97.3% | +254.7% | — | 10.3% |
|
VRTX
Vertex Pharmaceuticals Inc
|
$132.01B | +14.8% | +46.2% | 33.5 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$95.52B | +19.6% | +20.8% | 20.4 | 2.1% |
|
MRNA
Moderna, Inc.
|
$80.65B | +575.9% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$63.36B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 16, 2026
- This year
- 22
CG Oncology reported that PIVOT-006 met its primary endpoint, with cretostimogene reducing recurrence risk by 68% (hazard ratio 0.32; 95% CI: 0.23, 0.45; p<0.0001). BLAs are planned for March 2027 and the second quarter of 2027.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CGON | +16.8% | +31.0% | +38.3% | +26.6% | +97.3% |
| SPY | -5.5% | -6.3% | -5.6% | -5.3% | +5.0% |
| vs SPY | +22.2% | +37.3% | +43.9% | +31.9% | +92.3% |